SML3706

BT2

≥98% (HPLC)

• Sinónimos: 3,6-Dichloro-1-benzothiophene-2-carboxylic acid, 3,6-Dichlorobenzo[b]thiophene-2-carboxylic acid, 3,6-Dichlorobenzothiophene-2-carboxylic acid
• Fórmula empírica (notación de Hill): C₉H₄Cl₂O₂S
• Número de CAS: 34576-94-8
• Peso molecular: 247.10
• MDL number: MFCD00781745
• UNSPSC Code: 12352200
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: [s]1c2c(c(c1C(=O)O)Cl)ccc(c2)Cl
• InChI: 1S/C9H4Cl2O2S/c10-4-1-2-5-6(3-4)14-8(7(5)11)9(12)13/h1-3H,(H,12,13)
• InChI key: AAHPIJMQJAZYTM-UHFFFAOYSA-N

Descripción

Biochem/physiol Actions

BT2 is an orally active, allosteric mitochondrial branched-chain α-ketoacid dehydrogenase (BCKD) kinase (BCKDK or BDK) inhibitor (IC50 = 3.19 μM) that induces BDK dissociation from the BCKD complex (BCKDC) with superior pharmacokinetics and metabolic stability than (S)-CPP. BT2 increases cellular BCKDC activity in cultures (40 μM; MEF & murine hepatocytes) and induces BDK degradation in mice & rats in vivo, effectively upregulating tissue BCKDC activity and downregulating plasma branched-chain amino acid (BCAA) level. Typical dosing range: 40-250 μM (in cultures or cell-free), 20-40 mg/kg (ip. or po. in vivo; mice & rats) or 200 mg/kg diet.

Orally active, allosteric mitochondrial branched-chain α-ketoacid dehydrogenase complex (BCKDC) kinase (BCKDK, BDK) inhibitor in vitro and in vivo.

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable